☆ 4.5 Letter

Pharmaceutical industry-sponsored meals and prescriptions of biologics for asthma

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2023)

Journal

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE

Volume 11, Issue 9, Pages 2916-2918

Publisher

ELSEVIER

DOI: 10.1016/j.jaip.2023.05.030

Keywords

-

Categories

Allergy Immunology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Review Oncology

The Value of Pharmaceutical Industry-Sponsored Patient Registries in Oncology Clinical Research

E. Dawn Flick, Howard R. Terebelo, Susan Fish, Amani Kitali, Vrinda Mahajan, Melissa Nifenecker, Kristen Sullivan, Paul Thaler, Sarah Ussery, David L. Grinblatt

Summary: In May 2019, the FDA released guidelines on the potential use of real-world data in regulatory decisions. Patient registries, particularly in oncology/hematology settings, are seen as crucial in providing evidence of treatment effectiveness and safety. These registries collect large-scale clinical data to address important medical questions and are often used to generate real-world evidence.

ONCOLOGIST (2023)

Add to Collection

Review Pharmacology & Pharmacy

Biologics for severe asthma and beyond

Carlo Muemmler, Katrin Milger

Summary: Advancements in understanding the pathophysiology of type 2 inflammation in asthma have led to the development of targeted antibody therapies, which have been approved for the treatment of severe asthma. These medications have shown to reduce asthma exacerbations and oral corticosteroid use, and improve asthma control, quality of life, and lung function in suitable patients. Some patients with severe asthma may even achieve remission with ongoing biologic therapy. This article provides an overview of the six biologic therapies currently approved for severe asthma and reviews clinical trials and real-life studies on asthma and other type 2 inflammatory diseases. It also discusses the selection of biologics based on licensing criteria, asthma phenotype, and biomarkers, as well as monitoring treatment response and dealing with insufficient outcomes.

PHARMACOLOGY & THERAPEUTICS (2023)

Add to Collection

Review Pharmacology & Pharmacy

Dry powder pharmaceutical biologics for inhalation therapy

Rachel Yoon Kyung Chang, Michael Y. T. Chow, Dipesh Khanal, Donghao Chen, Hak-Kim Chan

Summary: Therapeutic biologics delivered through pulmonary route offer safe and effective treatment options for respiratory diseases, but require careful formulation strategies, manufacturing processes, and stability considerations.

ADVANCED DRUG DELIVERY REVIEWS (2021)

Add to Collection

Review Respiratory System

Biologics for severe asthma-Which, when and why?

Peer Ameen Shah, Chris Brightling

Summary: Asthma is a common chronic inflammatory condition affecting around 350 million people worldwide, with 5%-10% classified as severe cases. The management goal is to control symptoms, reduce exacerbations, and diminish corticosteroid-related morbidity. The advent of biologics has brought about a revolution in the treatment of severe asthma, particularly for those with type-2 mediated immunity. However, biologics are not a universal solution and there is still a significant unmet clinical need. This review explores the pathogenesis of asthma, different phenotypes, current and future biologic agents, selection and evaluation of biologic therapies.

RESPIROLOGY (2023)

Add to Collection

Review Pharmacology & Pharmacy

Particle engineering principles and technologies for pharmaceutical biologics

Dongmei Cun, Chengqian Zhang, Hriday Bera, Mingshi Yang

Summary: Pharmaceutical biologics have become integral in modern medicine, with most products being injections. Utilizing particulate delivery systems can enhance stability, intracellular uptake, pharmacological effects, bioavailability, and patient compliance. However, challenges remain in the development of particulate delivery systems for pharmaceutical biologics.

ADVANCED DRUG DELIVERY REVIEWS (2021)

Add to Collection

Article Allergy

Controversies in Allergy: Choosing a Biologic for Patients with Severe Asthma

Ian D. Pavord, Nicola A. Hanania, Jonathan Corren

Summary: The availability of various biological treatments targeting type-2 inflammation has opened up new possibilities for more severe asthma patients. However, the lack of direct comparative data makes it challenging to select the right biologic for each patient.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2022)

Add to Collection

Review Allergy

Global Variability in Administrative Approval Prescription Criteria for Biologic Therapy in Severe Asthma

Celeste M. Porsbjerg, Andrew N. Menzies-Gow, Trung N. Tran, Ruth B. Murray, Bindhu Unni, Shi Ling Audrey Ang, Marianna Alacqua, Mona Al-Ahmad, Riyad Al-Lehebi, Alan Altraja, Andrey S. Belevskiy, Unnur S. Bjornsdottir, Arnaud Bourdin, John Busby, G. Walter Canonica, George C. Christoff, Borja G. Cosio, Richard W. Costello, J. Mark FitzGerald, Joao A. Fonseca, Susanne Hansen, Liam G. Heaney, Enrico Heffler, Mark Hew, Takashi Iwanaga, David J. Jackson, Janwillem W. H. Kocks, Maria Kallieri, Hsin-Kuo Bruce Ko, Mariko Siyue Koh, Desiree Larenas-Linnemann, Lauri A. Lehtimaki, Stelios Loukides, Njira Lugogo, Jorge Maspero, Andriana Papaioannou, Luis Perez-de-Llano, Paulo Marcio Pitrez, Todor A. Popov, Linda M. Rasmussen, Chin Kook Rhee, Mohsen Sadatsafavi, Johannes Schmid, Salman Siddiqui, Camille Taille, Christian Taube, Carlos A. Torres-Duque, Charlotte Ulrik, John W. Upham, Eileen Wang, Michael E. Wechsler, Lakmini Bulathsinhala, Victoria Carter, Isha Chaudhry, Neva Eleangovan, Naeimeh Hosseini, Mari-Anne Rowlands, David B. Price, Job F. M. van Boven

Summary: The study identified significant differences in prescription criteria for biologics among 28 countries, posing a challenge to the implementation of personalized medicine for severe asthma treatment globally.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2022)

Add to Collection

Review Biochemistry & Molecular Biology

Asthma in the Precision Medicine Era: Biologics and Probiotics

Chiao-Juno Chiu, Miao-Tzu Huang

Summary: Asthma is a major global health issue affecting over 300 million people worldwide. The main goals of asthma management are to alleviate symptoms, reduce the risk of exacerbations, and minimize long-term medicinal adverse effects. Personalized precision therapy according to individualized clinical characteristics and laboratory biomarkers is the future prospect.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Add to Collection

Article Allergy

Relationship between inflammatory status and microbial composition in severe asthma and during exacerbation

Sarah Diver, Koirobi Haldar, Pamela Jane McDowell, John Busby, Vijay Mistry, Claudia Micieli, Vanessa Brown, Ciara Cox, Freda Yang, Catherine Borg, Rahul Shrimanker, Mohammadali Yavari Ramsheh, Tim Hardman, Joseph Arron, Peter Bradding, Douglas Cowan, Adel Hasan Mansur, Stephen J. Fowler, Jim Lordan, Andrew Menzies-Gow, Douglas Robinson, John Matthews, Ian D. Pavord, Rekha Chaudhuri, Liam G. Heaney, Michael R. Barer, Christopher Brightling

Summary: This study investigated the relationship between T2 biomarkers and airway microbial composition, as well as the effects of mepolizumab on airway ecology. The results showed that high FeNO levels may indicate a subgroup of severe asthma patients less likely to benefit from antimicrobial strategies, while low FeNO levels require biomarkers of microbial composition to identify patients likely to respond to microbiome-directed strategies. Additionally, mepolizumab did not alter airway microbial composition.

ALLERGY (2022)

Add to Collection

Review Immunology

Immunoregulation of asthma by type 2 cytokine therapies: Treatments for all ages?

Sejal Saglani, Laura Yates, Clare M. Lloyd

Summary: Asthma is a disease characterized by type 2 immune dysfunction, with excess secretion of cytokines and eosinophil inflammation. Efforts have been made to develop drugs targeting these immune pathways, but they are not curative and may not fully alleviate key features of the disease. This review discusses the current landscape of therapeutic options targeting type 2 immune cytokines and their efficacy and limitations in both adults and children with asthma.

EUROPEAN JOURNAL OF IMMUNOLOGY (2023)

Add to Collection

Article Allergy

Controversies in Allergy: Are Biologic Treatment Responses in Severe Asthma the Same in Adults and Children?

Courtney L. Gaberino, Leonard B. Bacharier, Daniel J. Jackson

Summary: The availability of biologic agents for severe asthma has increased, but selecting the right medication can be challenging due to lack of comparative data and biomarkers. Choosing biologics for pediatric patients is even more difficult due to limited options and trials. Treatment responses may vary between adult and pediatric patients.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2023)

Add to Collection

Article Respiratory System

Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics

Mark C. Liu, Bradley Chipps, Xavier Munoz, Gilles Devouassoux, Miguel Bergna, Steven G. Smith, Robert G. Price, Dmitry Galkin, Jay Azmi, Dalal Mouneimne, Frank C. Albers, Kenneth R. Chapman

Summary: The OSMO study showed that switching to mepolizumab resulted in beneficial responses in nearly all patients with uncontrolled severe eosinophilic asthma previously treated with omalizumab, regardless of baseline characteristics.

RESPIRATORY RESEARCH (2021)

Add to Collection

Review Biotechnology & Applied Microbiology

Blue technology for a sustainable pharmaceutical industry: Microalgae for bioremediation and pharmaceutical production

Miguel de Jesus Oliveira Santos, Carolina Oliveira de Souza, Henrique Rodrigues Marcelino

Summary: A microalgae biorefinery is an industrial facility that cultivates and fractionates microalgae biomass to produce raw materials. The pharmaceutical industry can be involved in a microalgae biorefinery through drug bioremediation and the use of active compounds. This study reviewed the progress in pharmaceutical removal by microalgae and emphasized its implications for biomass utilization, health promotion, and raw material production. Various microalgae were able to grow in the presence of pharmaceuticals and achieved comparable removal to conventional wastewater treatment. The removal mainly occurred through biodegradation or biotransformation processes.

ALGAL RESEARCH-BIOMASS BIOFUELS AND BIOPRODUCTS (2023)

Add to Collection

Review Biochemistry & Molecular Biology

The Pharmaceutical Industry in 2022: An Analysis of FDA Drug Approvals from the Perspective of Molecules

Beatriz G. G. de la Torre, Fernando Albericio

Summary: While the world was battling with the COVID-19 Omicron wave at the end of 2021, except for China, most countries ended 2022 with COVID-19 being treated like the flu. As a result, the U.S. Food and Drug Administration (FDA) only authorized 37 new drugs this year, compared to an average of 52 in the previous four years. This marks the second lowest number of drug approvals in the last six years, even though it may change in the future. The decrease in FDA approvals mainly applies to small molecule drugs, while biologics and TIDES have remained relatively constant.

MOLECULES (2023)

Add to Collection

Article Allergy

Biologics and global burden of asthma: A worldwide portrait and a call for action

M. Caminati, M. Morais-Almeida, E. Bleecker, I Ansotegui, G. W. Canonica, C. Bovo, G. Senna

Summary: Biologics for severe asthma can have a significant impact on disease burden and reduce asthma mortality. The availability of monoclonal antibodies is primarily limited to developed and high-income countries, while low and middle-income countries face higher asthma mortality rates due to poor socioeconomic conditions and lack of medical resources. Collaboration projects involving physicians internationally could potentially provide concrete opportunities to improve the overall healthcare systems for severe asthma.

WORLD ALLERGY ORGANIZATION JOURNAL (2021)

Add to Collection

Letter Rheumatology

Trend in Industry Payments to Rheumatologists in the United States During the COVID-19 Pandemic Between 2013 and 2021

Anju Murayama, Sae Kamamoto, Kenichi Higuchi, Haruki Shigeta, Akihiko Ozaki

JOURNAL OF RHEUMATOLOGY (2023)

Add to Collection

Article Rheumatology

Evaluation of Financial and Nonfinancial Conflicts of Interest and Quality of Evidence Underlying Psoriatic Arthritis Clinical Practice Guidelines: Analysis of Personal Payments From Pharmaceutical Companies and Authors' Self-Citation Rate in Japan and the United States

Hanano Mamada, Anju Murayama, Sae Kamamoto, Yudai Kaneda, Makoto Yoshida, Sota Sugiura, Erika Yamashita, Eiji Kusumi, Hiroaki Saito, Toyoaki Sawano, Tetsuya Tanimoto, Matt Vassar, Piotr Ozieranski, Akihiko Ozaki

Summary: This study aimed to assess financial conflicts of interest (COI) and nonfinancial COI among psoriatic arthritis (PsA) clinical practice guideline (CPG) authors in Japan and the US, and to evaluate the quality of evidence and strength of recommendations of PsA CPGs. The study found that approximately 91.3% of Japanese authors and 84.0% of US authors received at least one payment between 2016 and 2018. The average payment amount per author was $145,018 in Japan and $162,825 in the US. Furthermore, undisclosed financial COI were found in 78.3% of authors of the JDA PsA CPG and 48.0% of authors of the ACR PsA CPG.

ARTHRITIS CARE & RESEARCH (2023)

Add to Collection

Article Rheumatology

Financial Relationships Between Pharmaceutical Companies and Rheumatologists in Japan Between 2016 and 2019

Anju Murayama, Hanano Mamada, Haruki Shigeta, Takamichi Yoshinaga, Hiroaki Saito, Erika Yamashita, Tetsuya Tanimoto, Akihiko Ozaki

Summary: The study found that there is a prevalent and substantial financial relationship between rheumatologists and pharmaceutical companies in Japan. From 2016 to 2019, 92 major pharmaceutical companies paid a total of $55,246,485 in personal payments for lecturing, writing, and consulting to 5038 board-certified rheumatologists. These payments were primarily concentrated on doctors in authoritative and influential positions.

JCR-JOURNAL OF CLINICAL RHEUMATOLOGY (2023)

Add to Collection

Article Gastroenterology & Hepatology

Evaluation of financial conflicts of interest and quality of evidence in Japanese gastroenterology clinical practice guidelines

Anju Murayama, Sae Kamamoto, Nanami Murata, Ryota Yamasaki, Kohki Yamada, Erika Yamashita, Hiroaki Saito, Tetsuya Tanimoto, Akihiko Ozaki

Summary: This study found extensive financial conflicts of interest between pharmaceutical companies and guideline authors in Japan, with over 40% of recommendations based on low-quality evidence. The Japanese Society of Gastroenterology guideline development process lacks transparency and sufficient conflict of interest policies compared to global standards.

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2023)

Add to Collection

Article Cardiac & Cardiovascular Systems

Industry Payments During the COVID-19 Pandemic to Cardiologists in the United States

Anju Murayama, Sae Kamamoto, Haruki Shigeta, Akihiko Ozaki

Summary: Research in the US has revealed a funding relationship between pharmaceutical industries and physicians, especially cardiologists. This in-depth data analysis examines the impact of COVID-19 restrictions on this relationship. The results show a significant decline in payment amounts and frequencies for cardiologists following the onset of the pandemic. Cardiologists must consider the ethical implications of industry payments on their clinical practice.

CJC OPEN (2023)

Add to Collection

Letter Allergy

Industry-sponsored research funding to allergists and clinical immunologists in the United States

Anju Murayama

ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2023)

Add to Collection

Article Multidisciplinary Sciences

Pharmaceutical payments to Japanese board-certified dermatologists: a 4-year retrospective analysis of personal payments from pharmaceutical companies between 2016 and 2019

Anju Murayama, Sae Kamamoto, Hiroaki Saito, Akihiko Ozaki

Summary: There is a prevalent financial relationship between dermatologists and pharmaceutical companies in Japan. This study examined the personal payments made to board-certified dermatologists by the Japanese Dermatological Association from pharmaceutical companies between 2016 and 2019. The findings showed that a large number of dermatologists received personal payments, with an increasing trend over the four years, and higher payments were associated with certain dermatologist demographics.

SCIENTIFIC REPORTS (2023)

Add to Collection

Article Medicine, General & Internal

Cross-sectional analysis of pharmaceutical payments to Japanese board-certified gastroenterologists between 2016 and 2019

Anju Murayama, Sae Kamamoto, Moe Kawashima, Hiroaki Saito, Erika Yamashita, Tetsuya Tanimoto, Akihiko Ozaki

Summary: This study explores the financial relationships between pharmaceutical companies and gastroenterologists in Japan. The findings indicate that over half of board-certified gastroenterologists received personal payments totaling $89,151,253 from 84 pharmaceutical companies between 2016 and 2019. However, the study also reveals that only a few influential gastroenterologists accepted substantial amounts of payment.

BMJ OPEN (2023)

Add to Collection

Article Health Policy & Services

Japan's valsartan clinical trials shambles; time for fundamental changes

Akihiko Ozaki, Kayo Harada, Anju Murayama, Hiroaki Saito, Toyoaki Sawano, Tetsuya Tanimoto, Sunil Shrestha, Divya Bhandari, Andy Crump

Summary: This article discusses the Diovan(R)/valsartan scandal in Japan and highlights the issues with clinical research and biomedical publications in the country that need to be addressed to enhance public trust in clinical trials.

INTERNATIONAL JOURNAL OF HEALTH PLANNING AND MANAGEMENT (2023)

Add to Collection

Editorial Material Health Policy & Services

Generic drug crisis in Japan and changes leading to the collapse of universal health insurance established in 1961: the case of Kobayashi Kako Co. Ltd.

Makoto Kosaka, Akihiko Ozaki, Yudai Kaneda, Hiroaki Saito, Erika Yamashita, Anju Murayama, Hanano Mamada, Tetsuya Tanimoto, Mihajlo Jakovljevic

COST EFFECTIVENESS AND RESOURCE ALLOCATION (2023)

Add to Collection

Letter Infectious Diseases

Industry-sponsored research funding to infectious disease physicians in the United States between 2013 and 2021

Anju Murayama

CLINICAL MICROBIOLOGY AND INFECTION (2023)

Add to Collection

Letter Endocrinology & Metabolism

Evaluation of research and non-research industry payments to endocrinologists in the United States: An analysis of the Open Payments Database from 2014 to 2022

Anju Murayama

DIABETIC MEDICINE (2023)

Add to Collection

Article Medicine, General & Internal

Assessment of Financial Relationships Between Otorhinolaryngologists and Pharmaceutical Companies in Japan Between 2016 and 2019

Sae Kamamoto, Akihiko Ozaki, Anju Murayama

Summary: This study investigates the financial relationships between physicians and pharmaceutical companies in Japan, focusing on otorhinolaryngologists. It reveals that a significant number of otorhinolaryngologists received personal payments from pharmaceutical companies, with a concentration of payments among a small group of leading doctors.

CUREUS JOURNAL OF MEDICAL SCIENCE (2023)

Add to Collection

Article Respiratory System

A 9-Year Investigation of Healthcare Industry Payments to Pulmonologists in the United States

Anju Murayama, Hinari Kugo, Yoshika Saito, Hiroaki Saito, Tetsuya Tanimoto, Akihiko Ozaki

Summary: Nearly 90% of pulmonologists in the United States receive nonresearch and research payments from the healthcare industry, with nonresearch payments increasing continuously.

ANNALS OF THE AMERICAN THORACIC SOCIETY (2023)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.